Prospective Validation Study of High Volume Urine DNA Testing in Individuals with Suspicion of Urothelial Cancer

Launched by TAMPERE UNIVERSITY HOSPITAL · Mar 13, 2024

Keywords

ClinConnect Summary

The UROSCOUT-1 trial is researching a new way to test for urothelial cancer, which affects the bladder and urinary tract. This study is looking at urine tumor DNA testing, which involves analyzing DNA from urine samples, as a less invasive alternative to cystoscopy—a procedure where a thin tube is inserted into the bladder to look for cancer. Many people with blood in their urine undergo cystoscopy, but only a small number are actually found to have cancer. By using urine tests, the trial aims to improve patient comfort, lower healthcare costs, and ease the workload for doctors.

To participate in this trial, individuals must be between the ages of 65 and 75 and have a scheduled cystoscopy to check for urothelial cancer. Participants will need to provide consent and send in their urine samples by mail, which will be tested without knowing the patients' cancer status to ensure fairness. This study is open to all genders and is currently recruiting participants. If you or someone you know is facing a cystoscopy, this trial may offer a new testing option that could make the process easier and more efficient.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing and able to provide informed consent
• • Patient has been scheduled for cystoscopy to rule out urothelial cancer
• Exclusion Criteria:
• • Prior diagnosis of urothelial cancer (i.e. bladder cancer or upper tract urothelial carcinoma)